Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABLYF NASDAQ:ALLO NASDAQ:BOLD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABLYFAblynx$50.63$50.63$12.50▼$55.04$3.81B1.995,063 shsN/AALLOAllogene Therapeutics$1.90-2.1%$2.20$0.98▼$4.46$669.60M0.466.94 million shs5.04 million shsBOLDBoundless Bio$1.41+0.7%$1.44$0.96▼$1.68$31.45M0.659,703 shs141,117 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABLYFAblynx0.00%0.00%0.00%0.00%0.00%ALLOAllogene Therapeutics+2.11%+4.86%-3.00%-14.54%+44.78%BOLDBoundless Bio-0.71%-2.10%-6.04%+21.74%+32.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABLYFAblynx$50.63$50.63$12.50▼$55.04$3.81B1.995,063 shsN/AALLOAllogene Therapeutics$1.90-2.1%$2.20$0.98▼$4.46$669.60M0.466.94 million shs5.04 million shsBOLDBoundless Bio$1.41+0.7%$1.44$0.96▼$1.68$31.45M0.659,703 shs141,117 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABLYFAblynx0.00%0.00%0.00%0.00%0.00%ALLOAllogene Therapeutics+2.11%+4.86%-3.00%-14.54%+44.78%BOLDBoundless Bio-0.71%-2.10%-6.04%+21.74%+32.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABLYFAblynx 0.00N/AN/AN/AALLOAllogene Therapeutics 2.69Moderate Buy$8.52348.54% UpsideBOLDBoundless Bio 2.00Hold$4.00183.69% UpsideCurrent Analyst Ratings BreakdownLatest ALLO, BOLD, and ABLYF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026ALLOAllogene Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/1/2026BOLDBoundless Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/16/2026ALLOAllogene Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral4/14/2026ALLOAllogene Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$1.60 ➝ $3.854/14/2026ALLOAllogene Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $12.004/14/2026ALLOAllogene Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/14/2026ALLOAllogene Therapeutics ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$1.60 ➝ $3.854/14/2026ALLOAllogene Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$5.00 ➝ $8.004/14/2026ALLOAllogene Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.004/13/2026ALLOAllogene Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $10.004/10/2026ALLOAllogene Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABLYFAblynx$62.73M60.74N/AN/A$2.71 per share18.68ALLOAllogene Therapeutics$20K32,789.25N/AN/A$1.30 per share1.46BOLDBoundless BioN/AN/AN/AN/A$4.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABLYFAblynx-$122.67MN/AN/AN/AN/AN/AN/AN/AN/AALLOAllogene Therapeutics-$190.89M-$0.77N/AN/AN/AN/A-56.45%-40.36%8/12/2026 (Estimated)BOLDBoundless Bio-$58.20M-$2.50N/AN/AN/AN/A-53.60%-34.66%N/ALatest ALLO, BOLD, and ABLYF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A5/8/2026Q1 2026BOLDBoundless Bio-$0.51-$0.60-$0.09-$0.60N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABLYFAblynxN/AN/AN/AN/AN/AALLOAllogene TherapeuticsN/AN/AN/AN/AN/ABOLDBoundless BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABLYFAblynxN/AN/AN/AALLOAllogene TherapeuticsN/A9.659.65BOLDBoundless Bio0.529.879.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABLYFAblynxN/AALLOAllogene Therapeutics83.63%BOLDBoundless BioN/AInsider OwnershipCompanyInsider OwnershipABLYFAblynxN/AALLOAllogene Therapeutics13.20%BOLDBoundless Bio23.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABLYFAblynxN/A75.25 millionN/ANot OptionableALLOAllogene Therapeutics310345.15 million299.60 millionOptionableBOLDBoundless Bio6422.46 million17.28 millionNo DataALLO, BOLD, and ABLYF HeadlinesRecent News About These CompaniesBoundless Bio Halts Early Cancer Trial, Resetting Expectations for BOLDJune 8, 2026 | tipranks.comBoundless Bio Reports First Quarter 2026 Financial Results and Business HighlightsMay 8, 2026 | globenewswire.comBoundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at ...April 18, 2026 | caledonianrecord.comCBoundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual MeetingApril 17, 2026 | globenewswire.comBoundless Bio Terminates Major Long-Term San Diego LeaseApril 13, 2026 | tipranks.comNurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness StrategyApril 1, 2026 | globenewswire.comBoundless Bio (BOLD) price target increased by 33.33% to 4.08March 27, 2026 | msn.comBoundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American ...March 17, 2026 | caledonianrecord.comCBoundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026March 17, 2026 | globenewswire.comBoundless Bio, Inc.: Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsMarch 9, 2026 | finanznachrichten.deBoundless Bio beats fourth quarter loss estimatesMarch 9, 2026 | investing.comBoundless Bio posts smaller-than-expected Q4 lossMarch 9, 2026 | msn.comBoundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsMarch 9, 2026 | globenewswire.comBoundless Bio to Participate in the Leerink Global Healthcare ConferenceMarch 4, 2026 | globenewswire.comBoundless Bio, Inc. (BOLD) Upgraded to Buy: Here's WhyFebruary 13, 2026 | zacks.comBoundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026February 5, 2026 | tmcnet.comBoundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026February 5, 2026 | globenewswire.comWe're Keeping An Eye On Boundless Bio's (NASDAQ:BOLD) Cash Burn RateJanuary 31, 2026 | finance.yahoo.comBoundless Bio Inc.January 21, 2026 | money.usnews.comBoundless Bio secures FDA green light to launch cancer drug studyJanuary 20, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Robinhood Wants a Bigger Role in IPOs—Here's Why It MattersBy Leo Miller | June 14, 2026Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains CautiousBy Jennifer Ryan Woods | June 5, 2026ALLO, BOLD, and ABLYF Company DescriptionsAblynx OTCMKTS:ABLYF$50.63 0.00 (0.00%) As of 04/30/2019Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.Allogene Therapeutics NASDAQ:ALLO$1.90 -0.04 (-2.06%) Closing price 04:00 PM EasternExtended Trading$1.92 +0.03 (+1.32%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Boundless Bio NASDAQ:BOLD$1.41 +0.01 (+0.71%) Closing price 04:00 PM EasternExtended Trading$1.41 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
